APR 10, 2019 1:30 PM PDT

Detection and Interpretation of Complex Myeloid Leukemia Mutations

Sponsored by: QIAGEN
Speakers
  • Senior Global Product Manager of Personalized Healthcare/Oncology at QIAGEN
    Biography
      Dr. Véronique Laloux is Senior Global Product Manager of Personalized Healthcare/Oncology at QIAGEN. With 15 years of experience working for molecular diagnostic industries in sales, marketing and product management roles, Véronique is responsible for onco-hematology content development of PCR (ipsogen brand) and GeneReader NGS System (QIAact brand) assays. Véronique holds a Ph.D. in Molecular Biology and Biochemistry from University Pierre et Marie Curie, Paris 6, France.
    • Product Owner of QIAGEN Clinical Insight (QCI™) Intepret
      Biography
        Dr. Beate Litzenburger is the product owner of QIAGEN Clinical Insight (QCI™) Intepret. Prior to joining the QIAGEN team, Dr. Litzenburger led clinical decision support for several next generation sequencing research protocols at MD Anderson Cancer Center. In this role, Dr. Litzenburger was responsible for providing alteration interpretation, drug, and clinical trial options to clinicians. Dr. Litzenburger received her Ph.D. in molecular genetics from the University of Aachen in Germany and was a National Cancer Institute-supported post-doctoral fellow in the Department of Clinical Cancer Prevention at MD Anderson Cancer Center.

      Abstract

      Myeloid leukemias encompass a group of different diseases that include myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). These diseases are driven by somatic mutations acquired in 20-30 key genes. Given the genetic complexity of these heterogeneous disorders, there is an increasing need for molecular identification of key mutations across all of these genes. 

      In this webinar we will introduce two solutions for the detection and interpretation of mutations associated with myeloid leukemias.

      In the first half we introduce an integrated Sample to Insight NGS clinical research workflow for detection of myeloid leukemia mutations.  The QIAact Myeloid DNA UMI Panel in combination with the QIAGEN GeneReader™ NGS System provides a complete solution that can simultaneously test for around 9000 variants in 25 genes with reported relevance to clonal myeloid malignancy. The incorporation of unique molecular index (UMI) technology enables detection of even low-frequency variants, including JAK2 and KIT variants below the 1% variant allele frequency (VAF) and the KIT D816V mutation at 0.4% VAF. Accurate reporting of usually challenging-to-detect mutations such as the large CALR Type 1 (52 bp deletion), FLT3 ITDs (with identified insertion site), and GC-rich sequences such as in the CEBPA gene, are also possible due to the pairing of this digital sequencing approach with optimized bioinformatics. We will present clinical research data to show the successful detection and reporting low-frequency variants and challenging alterations with this complete assay.

      In the second half we present a bioinformatics solution for the clinical interpretation of somatic myeloid leukemia mutations. Cancer laboratories need rapid and reliable interpretation of identified genomic alterations. One of the challenges they face is producing standardized, reproducible interpretation and reporting of the most current and actionable information. QIAGEN Clinical Insight (QCI™) Interpret allows labs to deliver evidence-based, actionable insights. We will discuss the methodology and benefits of automating guidelines (AMP/ASCO/CAP and ACMG/AMP) for vetting somatic cancer alterations for actionability and pathogenicity in the same workflow while providing full transparency to the underlying evidence.

      Learning Objectives: 

      1. Understand the value of a tailored integrated Sample to Insight NGS workflow for the detection of complex mutations in myeloid leukemia
      2. Understand the value of standardized and consistent interpretation, especially for complex diseases like myeloid malignancies


      Show Resources
      You May Also Like
      MAY 11, 2021 10:00 AM PDT
      C.E. CREDITS
      MAY 11, 2021 10:00 AM PDT
      Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
      JUN 09, 2021 7:00 AM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      JUN 09, 2021 7:00 AM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
      APR 01, 2021 8:00 AM PDT
      C.E. CREDITS
      APR 01, 2021 8:00 AM PDT
      Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
      DEC 02, 2020 8:00 AM PST
      C.E. CREDITS
      DEC 02, 2020 8:00 AM PST
      DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
      MAY 18, 2021 8:00 AM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      MAY 18, 2021 8:00 AM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      Date: May 18, 2021 Time: 8:00am (PST) The global pandemic has caused an increased focus and scrutiny on molecular diagnostic assay development, resulting in a need for assays that provide qu...
      NOV 18, 2020 8:00 AM PST
      C.E. CREDITS
      NOV 18, 2020 8:00 AM PST
      DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
      APR 10, 2019 1:30 PM PDT

      Detection and Interpretation of Complex Myeloid Leukemia Mutations

      Sponsored by: QIAGEN

      Specialty

      Molecular Genetics

      Immunology

      Cancer

      Dna Sequencing

      Disease

      Tumor

      Cancer Research

      Personalized Medicine

      Research

      Flow Cytometry

      Cell

      Cancer Diagnostics

      T-Cells

      Clinical Genetics

      Clinical Medicine

      Geography

      North America61%

      Asia28%

      Europe6%

      Africa6%

      Registration Source

      Website Visitors100%

      Job Title

      Medical Laboratory Technician36%

      Clinical Laboratory Scientist21%

      Student14%

      Pharmacist7%

      Research Scientist7%

      Scientist7%

      Lab Management7%

      Organization

      Clinical Laboratory50%

      Academic Institution11%

      Hospital11%

      Life Science Company6%

      Biotech Company6%

      Medical School6%

      Government6%

      Other6%


      Show Resources
      Loading Comments...
      Show Resources
      Attendees
      • See more